- Conditions
- Posterior Fossa Ependymal Tumor
- Interventions
- Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS)
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
- Interventions
- Laboratory Biomarker Analysis, Natural Killer Cell Therapy
- Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fossa Ependymoma
- Interventions
- 5-Azacytidine and trastuzumab infusion
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain Tumor Recurrent
- Interventions
- Methotrexate, Etoposide, Ommaya Reservoir
- Drug · Procedure
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain Tumor Recurrent
- Interventions
- 5-Azacytidine
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Posterior Fossa Ependymoma (PFEPN)
- Interventions
- Trastuzumab after SubQ GM-CSF, Trastuzumab in combination with SubQ GM-CSF
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Recurrent Ependymoma
- Interventions
- 5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas